Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

5 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Three-year results of renal function in liver transplant recipients on low-dose sirolimus and tacrolimus: a multicenter, randomized, controlled trial.
Mulder MB, van Hoek B, van den Berg AP, Polak WG, Alwayn IPJ, de Jong KP, de Winter BCM, Verhey-Hart E, Erler NS, den Hoed CM, Metselaar HJ. Mulder MB, et al. Among authors: verhey hart e. Liver Transpl. 2023 Feb 1;29(2):184-195. doi: 10.1097/LVT.0000000000000003. Epub 2023 Jan 3. Liver Transpl. 2023. PMID: 36668691 Clinical Trial.
Health-related Quality of Life and Fatigue in Liver Transplant Recipients Receiving Tacrolimus Versus Sirolimus-based Immunosuppression: Results From a Randomized Trial.
Mulder MB, Busschbach JV, van Hoek B, van den Berg AP, Polak WG, Alwayn IPJ, de Winter BCM, Verhey-Hart E, Erler NS, den Hoed CM, Metselaar HJ. Mulder MB, et al. Among authors: verhey hart e. Transplantation. 2023 Dec 1;107(12):2545-2553. doi: 10.1097/TP.0000000000004619. Epub 2023 May 16. Transplantation. 2023. PMID: 38010321 Clinical Trial.
Modifying Tacrolimus-related Toxicity After Liver Transplantation Comparing Life Cycle Pharma Tacrolimus Versus Extended-released Tacrolimus: A Multicenter, Randomized Controlled Trial.
Mulder MB, van Hoek B, Polak WG, Alwayn IPJ, de Winter BCM, Darwish Murad S, Verhey-Hart E, Elshove L, Erler NS, Hesselink DA, den Hoed CM, Metselaar HJ. Mulder MB, et al. Among authors: verhey hart e. Transplant Direct. 2024 Mar 12;10(4):e1612. doi: 10.1097/TXD.0000000000001612. eCollection 2024 Apr. Transplant Direct. 2024. PMID: 38481963 Free PMC article.
Predicting treatment outcome following 24 weeks peginterferon alpha-2a/ribavirin therapy in patients infected with HCV genotype 1: utility of HCV-RNA at day 0, day 22, day 29, and week 6.
Lukasiewicz E, Hellstrand K, Westin J, Ferrari C, Neumann AU, Pawlotsky JM, Schalm SW, Zeuzem S, Veldt BJ, Hansen BE, Verhey-Hart E, Lagging M. Lukasiewicz E, et al. Among authors: verhey hart e. Hepatology. 2007 Jan;45(1):258-9. doi: 10.1002/hep.21505. Hepatology. 2007. PMID: 17187414 No abstract available.